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Background:The novel Coronavirus Disease 2019 (COVID-19) outbreak, caused by the pathogenic severe acute 
respiratory syndrome-2 (SARS-CoV-2) virus, is exponentially spreading across the globe. 
Methods: The current systematic review was performed utilising the following electronic databases PubMed, 
MEDLINE and EMBASE. We searched for the keywords "COVID-19 AND "pregnancy" between January 1, 2020 
until December 31, 2020. 
Results: Out of 4005 records which were identified, 36 original studies were included in this systematic review. Pooled 
prevalence of vertical transmission was 10%, 95% CI: 4-17%. Pooled prevalence of neonatal mortality was 7%, 95% CI: 0-
21%. 
Conclusion: The contemporary evidence suggests that the incubation period of COVID-19 is 2-14 days, and this 
infection could be transmitted even from the infected asymptomatic individuals. It is found that the clinical 
presentation of pregnant women with COVID-19 infection is comparable with the infected non-pregnant females, and 
the frequent symptoms were fever, cough, myalgia, sore throat and malaise. Some cases have severe maternal 
morbidity and perinatal deaths secondary to COVID-19 infection. Under these circumstances, pregnant women should 
focus on maintaining personal hygiene, proper nutrition and extreme social distancing to reduce the risk of COVID-
19. Therefore, systematic data reporting for evidence based clinical assessment, management and pregnancy outcomes 
is essential for preventing of COVID-19 infection among pregnant women. 






The current pandemic of novel coronavirus disease 2019 
(COVID-19) has accounted for more than 3 million infections 
with over 210,000 infection-related deaths worldwide [1]. It is 
considered a severe public health emergency due to a higher rate 
of infectivity and deadly nature affecting all ages and both 
genders. Particularly vulnerable populations including pregnant 
women, the elderly, adults with co-morbidities and paediatrics, 
are at increased risk of complications. Inadequate healthcare 
resources and workforce can further compromise the care of 
vulnerable individuals. The substantial morbidity associated 
with the disease and potential socioeconomic impact 
necessitates the implementation of drastic preventive measures 
across all continents, such as nationwide lockdowns and closure 
of borders. Notably, the current evidence suggests that COVID-
19 infection has significant impacts on pregnant women and 
foetuses similar to the risk of complications associated with the 
2009 pandemic of H1N1 influenza virus among pregnant 
women and the severe effects of Zika virus infections on foetal 
outcomes [2-5]. Concerning the maternal immune system 
during pregnancy, there is a cell-mediated immunity shift from 
T-helper 1 (Th1) towards the proliferation of T-helper 2 (Th2) 
cells which safeguard the foetus, but at the same time keeps the 
mother more vulnerable to infections, which the Th1 immune 
system can better protect. The unique immune system changes 
during pregnancy necessitate an integrated multispecialty 
approach for managing COVID-19 positive pregnant females. 
The current literature reported that the outcomes of 55 COVID-
19 positive pregnant females and 46 newborns did not suggest 
the possibility of mother-to-foetus transmission of SARS-CoV-
2 infection [6].  Similarly, the International Society of 
Infectious Disease in Obstetrics and Gynecology (ISIDOG) 
guidelines also suggested no indication of vertical transmission 
of COVID-19 during the second or third trimester of pregnancy 
[7]. 
The rapid onset of the COVID-19 outbreak significantly 
impacts the medical and public health facilities.  So vulnerable 
groups, including pregnant women, should focus on infection 
prevention and management through strategic preparedness and 
evidence-based response planning. In the previous Ebola 
outbreak, clinicians are often cautious about treating or 
providing vaccination to pregnant women considering the foetal 
outcomes [8]. It is crucial to ensure that women receive 
substantial life-saving treatment despite the threat of a 
contagious disease unless there is a serious clinical 
contraindication. Moreover, it is necessary to carefully assess 
the potential benefits and risks of the interventions prior to 
clinical-decision making to treat infected pregnant women. As 
surveillance systems for COVID-19 positive patients are being 
established, it is crucial to analyse the maternal and foetal 
outcomes during pregnancy. 
Interestingly, in the current COVID-19 outbreak, 
proportionally, more men are affected than women [9]. This 
gender disparity can be attributed to the variability in the 
reporting system, susceptibility of exposure, screening and 
diagnosis of infection. Notably, the frequently reported 
symptoms of COVID-19 are cough (82%), fever (83%) and 
shortness of breath (31%) among hospitalised patients and 
elderly males with associated co-morbidities are more likely to 
show severe respiratory distress [10]. As there is limited 
published data, the possible susceptibility of pregnancy towards 
COVID-19 infection or the potential risk of miscarriage or 
foetal anomalies remains unclear. 
Methodology  
Literature Searches  
The current systematic literature review was performed utilising 
electronic databases PubMed, MEDLINE and EMBASE. We 
searched for the keywords "COVID-19 AND "pregnancy" 
between January 1, 2020, until December 31, 2020. Due to the 
rapid onset of the COVID-19 pandemic, literature is scarce on 
this topic, so all articles were considered for analysis. Medical 
subject headings (MeSH) terms used were “2019-nCoV” 
[Title/Abstract] OR “2020-nCov” [Title/Abstract] OR “2019-
20 coronavirus*” [Title/Abstract] OR “2019-2020 
coronavirus*” [Title/Abstract] OR “2019 coronavirus*” 
[Title/Abstract] OR “coronavirus* 2019” [Title/Abstract] OR 
“2020 coronavirus*” [Title/Abstract] OR “coronavirus* 2020” 
[Title/Abstract] OR “SARS-CoV-2” [Title/Abstract] OR 
“SARS coronavirus 2” [Title/Abstract] OR “COVID-19” 
[Title/Abstract] OR “COVID-2019” [Title/Abstract] OR 
“coronavirus disease 2019” [Title/Abstract] OR “coronavirus 
disease 2020″[Title/Abstract]))) AND “Pregnancy”. All the 
extracted relevant articles were considered for the review 
analysis. All research articles describing the epidemiology, 
clinical characteristics and management of COVID-19 in 
pregnancy were included during the mentioned period. 
Inclusion/Exclusion Criteria 
We included all published articles in the English language 
accessible on electronic databases and specific institutional 
sites. The retrieved articles were independently assessed and 
evaluated by five authors for inclusion.  This process resulted in 
the selection of 36 articles related to clinical characteristics and 
management of COVID-19 in pregnancy for this review [11-
46]. We have also utilised the bibliography of the retrieved 
articles (this process is also known as hand-searching), to look 







Databases PubMed, MEDLINE and EMBASE were initially 
searched thoroughly for appropriate titles. The selected titles 
were then screened for the abstracts and full texts. Articles that 
met the eligibility requirements were considered for this 
systematic review. Five researchers independently conducted 
the literature evaluation (BS, HAlH, IB, MA, and AA). The 
extracted data include study authors, year, Sample size Study 
design, Confirmed SARS-CoV-2, Vertical transmission, 
Maternal mortality, Neonatal mortality, Age, Gestational Age 
(delivery), Maternal comorbidities, Clinical features- Fever on 
admission Fever after childbirth, Cough, Malaise, Dyspnea, 
Myalgia, Sore Throat, Diarrhoea, Laboratory characteristics, 
CT scan, Treatment, Delivery characteristics, Maternal 
outcome and Neonatal outcome. 
Methodology Quality Assessment 
The selected studies were assessed for methodological quality 
based on study design, case ascertainment, case definition, 
patient population, and the methodology description. We used 
the Joanna Briggs Institute (JBI) Critical Appraisal Checklist 
for Analytical Cohort studies, with 11 domains assessing, 
simithe larity between groups, the similarity between 
exposures, validity and reliability of the exposure, cofounding 
factors, freeness of the outcome, measurement of the outcomes, 
follow-up time and statistical analysis. 
Data Analysis and Synthesis 
Prevalence was calculated for categorical variables. The 
decision to select either fixed effect or random effects model 
depended on the results of statistical tests for heterogeneity. 
Data heterogeneity was assessed using the Cochrane Q 
homogeneity test (significance set at p < 0.10). If the studies 
were statistically homogeneous, a fixed-effect model was 
selected. A random-effects model was used when studies were 
statistically heterogeneous. The Higgin’s I2 test is the ratio of 
true heterogeneity to the total variation in observed effects. A 
rough guide to the interpretation of the I2 test is 0-25%: might 
not be significant; 25-50%: may represent moderate 
heterogeneity; 50-75%: may represent substantial 
heterogeneity; and > 75%: considerable heterogeneity. 
Publication bias was visually estimated by assessing funnel 
plots. Pooled estimates were calculated using R 3.5.1 software. 
Results 
Out of 4005 records that were identified, 476 duplicates were 
removed. One hundred eighty-nine records were screened, 
reviews, letters, news articles, patient-education handouts, 
retracted papers were excluded. Finally, 36 original studies 
were included in this systematic review. 
We used the PRISMA diagram to illustrate the flow of 
information through the different phases of the systematic 
review, it maps out the number of records identified, included 
and excluded (Figure 1). 
Quality assessment  
The risk of bias of included studies was assessed,  for figure 
elaboration and analysis we implemented Risk-of-bias 
VISualization (robvis): An R package and Shiny web app for 
visualizing risk-of-bias assessments as shown in Figures 2 and 
3. Overall quality was low in the studies found; nevertheless, 
the domains of follow-up time, loss to follow up and strategies 
to address incomplete follow up were deficient in most of the 
studies because of no clear description or a statement in this 
regard. 
Table 1 depicts the characteristics of studies included in this 
systematic review. Out of 36 original studies, 22 studies were 
conducted in China, nine in the USA (United States of 
America), two in the UK (United Kingdom), and one each in 
Italy, Portugal, and Iran. Two studies were case-control [11, 
18], one was retrospective prospective study [25], two were 
prospective [32, 33], the remaining 31 studies were 
retrospective [12-17, 19-24, 26-31, 34-46]. The sample size and 
confirmed COVID-19 (%) are shown in Table 1.  
Table 2 determines the maternal characteristics, consisting of 
maternal age and gestational age during delivery. The age of the 
patient was raging from 19-41 and gestational age was 31-41 
weeks. Table 3 depicts the mode of delivery comprised of 
caesarean section, preterm delivery, vaginal delivery and the 
total number of deliveries. The caesarean section was the 
preferred method of delivery in a study conducted by Na Li et 
al. [11]. The procedure was conducted in 87.5% of confirmed 
cases and 88.9% in suspected cases. In all 100% of cases, 
caesarean section was performed in the studies conducted by 
H.Chen et al., Yu et al., Chen et al., Fan et al., Khan et al., 
Hirshberg et al., and Cooke et al [12, 15, 16, 27, 31, 37, 40],. 
Vaginal delivery was the least preferred mode of delivery in all 
the selected studies. In a study conducted by Pierce-Williams et 
al., 88% were preterm delivery in severe COVID-19 patients. 
Table 4 shows the clinical features of pregnant women due to 
COVID-19 viz. fever, cough, malaise, dyspnoea, myalgia, sore 
throat. The studies conducted by Khan et al. and Zheng et al. 
showed fever on admission in 66.7% and 73% cases [14,26]. 
Cough was present in 100% of patients in the study conducted 
by Khan et al [26]. In 60% of the cases in a study conducted by 
D. Liu et al. [19] myalgia and sore throat were not common 
clinical features.               
Table 5 elicits the various laboratory findings, including 
lymphocytopenia, elevated CRP concentration, and confirmed 
SARS- Cov -2 cases. Table 6 shows the CT Scan findings of the 
patients.  
Various pharmacological approaches of the patients are 




patients. In a study conducted by Na Li et al. 100% of confirmed 
and suspected cases received antibiotics [11].  Similarly in 
studies conducted by H.Chen et al. 100%, Yu et al. 100%, D. 
Liu et al. 100%, C.Wu et al. 100%, Khan et al. 100%, Fan et al. 
100%, Xu et al. 100%, and Hantoushzadeh et al. 100% patients 
received antibiotics therapy [12, 15, 19, 23, 26, 27, 35, 36].  
Other modes of therapy were antiviral drugs, which were 
prescribed in 67% of cases in a study conducted by H. Chen al. 
and in 100% cases in the studies conducted by Yu et al., 
Hantoushzadeh et al., Hirshberg et al., Xu et al. and Khan et al. 
respectively[12, 15, 26, 36, 37, 35, 31]. High-flow 02 was given 
in 100% cases in studies conducted by H. Chen et al. and Yu et 
al. [12, 15]. Table 8 shows maternal comorbidities and maternal 
outcomes. A study conducted by Hantoushzadeh et al. reported 
77% maternal mortality and a maternal ICU (Intensive Care 
Unit) admission of 77%  Cooke et al. showed a maternal ICU 
admission in 100% of cases. In comparison, other studies 
included in this systematic review did not report high 
percentages of maternal ICU admission.         
Table 9 shows the neonatal outcomes which varied a lot:  1% of 
neonatal death was reported by Yan et al., 36% by 
Hantoushzadeh et al., 13% by Lokken et al. and 2% by London 
et al., respectively [20, 36, 42, 44]. Other neonatal outcomes 
such as Intrauterine Fetal Death, Vertical Transmission, 
Intrauterine Fetal Distress, Mean Birth Weight, Low Birth 
Weight, APGAR score at 1 minute and five after birth is shown 
in Table 8. 
Outcome measures  
Figure 4 depicts the meta-analysis of the four studies of 
pregnant COVID-19 patients based on their vertical 
transmission. Pooled prevalence of vertical transmission was 
10%, 95% CI: 4-17% (Figure 4).  
Figure 5 depicts the meta-analysis of the four pregnant COVID-
19 patient studies based on neonatal mortality. Pooled 
prevalence of neonatal mortality was 7%, 95% CI: 0-21% 
(Figure 5).  
Heterogeneity among included studies 
The results for the heterogeneity test for the meta-analysis of 
the vertical transmission and neonatal mortality among 
pregnant COVID 19 patients are displayed towards the bottom 
of the Forest plot in the line. For vertical transmission group, Q 
[χ2]=1.43, P=0.70, I2=0%, (Figure 4).  However, I2 was<25%, a 
fixed-effect model was considered for vertical transmission. For 
the neonatal mortality group, Q [χ2] =13.91, P=0.001, I2=78%, 
tau2=0.109 (Figure 5). However, I2 was>25%, a random-effect 
model was considered for neonatal mortality.  
Publication bias and funnel plots 
For all of the above analyses, sensitivity analysis yielded 
consistent results. Based on a visual inspection of the funnel 
plot, there was evidence of publication bias for the included 
studies (Figure 6 and 7). The funnel plots exhibited studies with 








































































































Records identified from: 
Databases (n = 4005 ) 
Registers (n = 0) 
Records removed before 
screening: 
Duplicate records removed  
(n = 476) 
 
Records screened 
(n = 3529) 
Records excluded (Reviews, 
letters, news articles, patient-
education handouts, retracted 
papers removed) 
(n = 3339) 
Reports assessed for eligibility 
(n = 188) 
Studies un-related to the 
topic, and relevant studies 
without full texts excluded 
(n=152) 
Studies included in systematic 
review 
(n = 36) 
Studies included in meta-
analysis (n = 4) 



























Figure 2: Risk of Bias 
 
 





Figure 3: Risk of bias summary  
 
Review authors' judgements about each risk of bias item presented as percentages across all included studies. 
 
Figure 4: Forest plot of pregnant COVID 19 patients based on their vertical transmission 
 
 













Figure 7. Funnel plot of COVID-19 pregnant patients based on their neonatal mortality 
 
Table 1: Characteristics of studies included in the systematic review 
Author, year (Country) Sample size (N) Study design Confirmed SARS-CoV-2 (%) 
Na Li, et al. 2020 (China) [11] 276 Retrospective case-control 16/276 (6.0) 
H.Chen, et al. 2020 (China) [12] 9 Retrospective 9/9(100) 
S. Chen. et al. 2020 (China) [13] 5 Retrospective 5/5(100) 
Zhu et al. 2020 (China) [14] 9 Retrospective 9/9(100) 
Yu, et al. 2020 (China) [15] 7 Retrospective 7/7(100) 
R.Chen, et al. 2020 (China) [16] 17 Retrospective 17/17 (100) 
H.Liu, et al. 2020 (China) [17] 41 Retrospective 41/41 (100) 
Yang, et al. 2020 (China) [18] 55 Retrospective case-control 13/55(24) 
D.Liu, et al. 2020 (China) [19] 15 Retrospective 15/15(100) 
Yan, et al. 2020 (China) [20] 116 Retrospective 65/116(56.0) 
Breslin, et al. 2020a (USA) [21] 43 Retrospective 43/43 (100) 
Breslin, et al. 2020b (USA) [22] 7 Retrospective 7/7(100) 
C.Wu, et al. 2020 (China) [23] 8 Retrospective 8/8 (100) 
X.Wu, et al. 2020 (China) [24] 23 Retrospective 23/23 (100) 






Khan, et al. 2020a (China) [26] 3 Retrospective 3/3 (100) 
Fan, et al. 2020 (China) [27] 2 Retrospective 2/2(100) 
Y. Chen, et al. 2020 (China) [28] 4 Retrospective 4/4(100) 
Campbell, et al.2020 (USA) [29] 30 Retrospective 30/30 (100) 
Baergen, et al.  2020 (USA) [30] 20 Retrospective 20/20 (100) 
Khan, et al. 2020b (China) [31] 17 Retrospective 17/17 (100) 
Zheng, et al. 2020 (China) [32] 33 Prospective 33/33 (100) 
W.Liu, et al. 2020 (China) [33]  19 Prospective 19/19 (100) 
Cao, et al. 2020 (China) [34] 10 Retrospective 10/10 (100) 
Xu, et al. 2020 (China) [35]  5 Retrospective 5/5 (100) 
Hantoushzadeh, et al. 2020 (Iran)[36] 9 Retrospective 9/9(100) 
Hirshberg, et al. 2020 (USA) [37] 5 Retrospective 5/5 (100) 
Qiancheng, et al. 2020 (China) [38] 28 Retrospective 28/28 (100) 
Hu, et al.  2020 (China) [39] 7 Retrospective 7/7 (100) 
Cooke, et al. 2020 (UK) [40] 2 Retrospective 2/2 (100) 
Doria,  et al. 2020 (Portugal) [41] 12 Retrospective 12/12 (100) 
Lokken, et al.  2020 (USA) [42] 46 Retrospective 46/46 (100) 
Savasi, et al. 2020 (USA) [43] 77 Retrospective 77/77 (100) 
London, et al. 2020 (USA) [44] 68 Retrospective 68/68 (100) 
Govind, et al. 2020 (UK) [45]  9 Retrospective 9/9 (100) 
Ferrazi, et al. 2020 (Italy) [46] 42 Retrospective 42/42 (100) 
 
Table 2:  Maternal characteristics 
Authors Age Gestational Age (delivery) 
Na Li et al. 2020 [11]    
Confirmed Case (16) 30.9 ±3.2 38±0.2  
Suspected Case (18) 29.8 ± 2.3 38±2. 9 
Control 2020 (121) 30.1 ± 3.3 39±0.7 
Control 2019 (121) 29.3 ± 2.6 38±6.9 
H.Chen, et al. 2020 [12] 29.8 years 36-39 wks + 4 days 
S.Chen. et al. 2020 [13] 29 years 38-41 weeks 
Zhu et al. 2020 [14] 31 years 31-39 weeks 
Yu, et al. 2020  [15] 32 years 39 weeks + 1 day 
R.Chen, et al. 2020 [16] 29.1 years >37 weeks 
H.Liu, et al. 2020 [17] 31 years - 
Yang, et al. 2020  [18]     
Confirmed (13) 30.2 ± 2.3 38.2 ± 2.3 
Control (42) 29.8 ± 3.4 38.8 ± 1.8 
D.Liu, et al. 2020  [19] 32 ± 5 32 ± 8 
Yan, et al. 2020 [20] 30.8 ± 3.8  38.0 (36.0,39.1)  
Breslin, et al. 2020a [21] 29.7 ± 6.0  37 weeks 
Breslin, et al. 2020b [22] 33.8 years 33 weeks+3 days 
C.Wu, et al. 2020 [23] 29.8 33.3 
X.Wu, et al. 2020  [24] 29 - 
Pierce-Williams, et al. 2020 [25]     
Severe (44) 32.0±6.0  37.7±1.6 
Critical (20) 35.9±4.3  31.9±3.8  




Fan, et al. 2020 [27] 31.5 36-38 
Y.Chen, et al. 2020 [28] 29 37-39 weeks 
Campbell, et al. 2020 [29] 30-35 37 weeks 
Baergen, et al.  2020 [30] 19-41  32-40 weeks 
Khan, et al. 2020b [31] 37.82 38.1 
W.Liu, et al. 2020 [33]  31 38.6±1.5 
Cao, et al. 2020 [34] 29-35 33-40  
Xu, et al. 2020  [35]  29 36.4±3 
Hantoushzadeh, et al. 2020 [36] 32 24-38 
Hirshberg, et al. 2020 [37] 33 25-31 
Qiancheng, et al. 2020  [38] 30 (26.75–32) 38 (36.5–39) 
Hu, et al.  2020 [39] 33 37-41 
Cooke, et al. 2020 [40] 34 28 
Doria, et al. 2020  [41] 32 30-41 
Lokken, et al.  2020 [42] 29 (26-34) 27 weeks 
Savasi, et al. 2020 [43] 32 37 
London, et al. 2020 [44] 30 years 65/68 in 3rd tri 
Govind, et al. 2020 [45]  31 (18-39) 39 weeks 
Ferrazi, et al. 2020 [46] 21-44 30 weeks 
 
Table 3: Delivery characteristics 
Authors Total Number 
of Deliveries 
Pt. not delivered during 




Na Li et al. 2020[11]           
Confirmed Case (16) 152/276 (55.0) 124/276 (45.0) 14/16(87.5) 3 /16 (18.8) 2/16(12.5) 
Suspected Case (18) 
  
16/18 (88.9) 3/18 (16.7) - 
Control 2020 (121) 
  
57/121 (47.1) 7/121 (5.8) - 
Control 2019 (121) 
  
44 /121(36.4) 6/121 (5.0) - 
H.Chen, et al. 2020 [12] 9/9(100) - 9/9(100) 4/9(44) - 
S.Chen. et al. 2020 [13] 5/5(100) - 2/5(40) - 3/5(60) 
Zhu et al. 2020 [14] 9/9(100) - 7/9(78) 5/9(56) 2/9(22) 
Yu, et al. 2020  [15] 7/7(100) - 7/7(100) - - 
R.Chen, et al. 2020 [16] 17/17 (100) - 17/17 (100) 3/17 (18) - 
H.Liu, et al. 2020 [17] 16/41 (39) 25/41 (61) - - - 
Yang, et al. 2020  [18]           
Confirmed (13) 55/55 (100) - 9/13(69.2) - 4/13(30.8) 
Control (42) 
  
30/42(71.4) - 12/13(28.6) 
D.Liu, et al. 2020  [19] 11/15 (73) 4/15(27) 10/11(91) - 1/11(9) 
Yan, et al. 2020 [20] 99/116 (85.3) 17/116 (14.6) 85/99 (85.9) 21/99 (21.2) 14/99(14.1) 
Breslin, et al. 2020a [21] 18/43 (41.9) 25/43(58.1) 8/18(44.4) - 10/18(55.5) 
Breslin, et al. 2020b [22] - - - - - 
C.Wu, et al. 2020 [23] 8/8 (100) - 6/8 (75) 1/8 (12.5) 2/8(25) 
X.Wu, et al. 2020 [24] 20/23 (86.9) - 18/20(90) - 2/20 (10) 





Table 4: Presenting signs and symptoms 




Cough Malaise Dyspnea Myalgia Sore 
Throat 
Diarrhea 
Na Li et al. 2020 [11]                 
Confirmed Case (16) 4/16 (25.0) 1/16 (5.6) - - - - - - 
Suspected Case (18) 1 /18(5.6) 6/18 (33.3) 1/18 (5.6) - 1/18 (5.6) - 1 /18(5.6) - 
Control 2020 (121) - - - - - - - - 
Control 2019 (121) - - - - - - - - 
S.Chen. et al. 2020 [13] - 5/5(100) 1/5(20) - - - - - 
Zhu et al. 2020 [14] 4/9(44) 2/9(22) 4/9(44) - - - 1/9(11) 1/9(11) 
Yu, et al. 2020  [15] 6/7(86) - 1/7(14) - 1/7(14) - - - 
R.Chen, et al. 2020 [16] 4/17  (24) - 4/17 (24) 1/17 (6) 1/17 (6) - 1/17 (6) - 
H.Liu, et al. 2020 [17] 16/41 (39) 14/41 (34) 15/41 (37) 5/41 (12) 5/41 (12) - - - 
Yang, et al. 2020  [18]                 
Confirmed (13) 2/13(15.4) 8/13(61.5) - - - - - - 
Control (42) 11/42(26.2) 20/42(47.6) - - - - - - 
D.Liu, et al. 2020  [19] 13/15(87) 1/11(9) 9/15(60) 4/15(27) 1/15(7) 3/15(20) 1/15(7) 1/15(7) 












Breslin, et al. 2020a [21] 14/29 (48.3) - 19/29 (65.5) 11/29 (38) 7/29(24.1) - - - 
Breslin, et al. 2020b [22] 2/7 (28.5) - 3/7 (43.0) - - 3/7(43.0) - - 
C.Wu, et al. 2020 [23] 1/8(12.5) 3/8(37.5) - - - - - - 
Severe (44) 15/44 (34) 29/44 (66) 8/15 (53%) 4 /15 (27%)  7/15 (47%)  
Critical (20) 17/20 (85) 3/20 (15) 16/17 (94%)  15/17 (88%) 1/17 (6%) 
Khan, et al. 2020a [26] 3/3(100) - - 1/3 (33.3) 3/3 (100) 
Fan et al. 2020 [27] 2/2 (100) - 2/2 (100) - - 
Y.Chen, et al. 2020 [28] 4/4 (100) - 3/4 (75) - 1/4(25) 
Campbell, et al.2020 [29] 10/30 (33) 20/30 (66) 10/30 (33) - - 
Baergen, et al.  2020 [30] 17/20 (85) - 5/20 (25) - 15/20 (75) 
Khan, et al. 2020b [31] 17/17 (100) - 17/17 (100) 5/17 (29.4) - 
Zheng, et al. 2020 [32] 33/33 (100) - 27/33 (81) 4/33 (12) - 
W.Liu, et al. 2020 [33]  19/19 (100) - 18/19 (95) - 1/19 (5) 
Cao, et al. 2020 [34] 10/10 (100) - 8/10 (80) 3/10 (30) 2/10 (20) 
Xu, et al. 2020  [35]  10/10(100) - 4/5 (80) 2/5 (40) 1/5 (20) 
Hantoushzadeh, et al. 2020 [36] 11/11 (100) 2/11 (18) 8/11 (73) 4/11 (36) 1/11 (9.1) 
Hirshberg, et al. 2020 [37] 3/5 (60) 2/5 (40) 3/3 (100) 3/3 (100) - 
Qiancheng, et al. 2020  [38] 23/28 (82) 5/28 (18) 17/23 (74) 01/23 (4) 5/23 (22) 
Hu, et al.  2020 [39] 7/7 (100) - 6/7 (86) - 1/7 (14) 
Cooke, et al. 2020 [40] 2/2 (100) - 2/2 (100) 2/2 (100) - 
Doria, et al. 2020  [41] 10/12 (83) 2/12 (17) 6/10 (60) - 4/10 (40) 
Lokken, et al.  2020 [42] 8/46 (17) - 3/8 (37.5) 1/8 (12.5) 5/8 (62.5) 
Savasi, et al. 2020 [43] 57/77 (74) 20/77 (26) 34/57 (61) 12/57 (21) 23/57 (39) 
London, et al. 2020 [44] 55/67 (82) 12/67 (18) 22/55 (40) 12/55 (22) 33/55 (60) 
Govind, et al. 2020 [45]  9/9 (100) - 8/9 (89) 2/9 (22) 1/9 (11) 




X.Wu, et al. 2020 [24] 4/23(17.4) - 6/23(26.1) - - - - - 
Pierce-Williams, et al. 
2020 [25] 
                
Severe (44) - - - - - - - - 
Critical (20) - - - - - - - - 
Khan, et al. 2020a [26] 2/3 (66.6) - 3/3 (100) - 1/3 (33.3) - - - 
Fan, et al. 2020 [27] 1/2 (50) - - - 1/2 (50) - - 1/2 (50) 
Y.Chen, et al. 2020 [28] 3/4(75) - 2/4(50) 2/4(50) 2/4(50) - - - 
Campbell, et al.2020 [29] - - - - - - - - 
Baergen, et al.  2020 [30] 10/20 (50) - - - - - - - 
Khan, et al. 2020b [31] 3/17 (18) - 6/17 (35) - 2/17 (12) - - 3/17 (18) 
Zheng, et al. 2020 [32] 24/33 (73) 15/33 (45) 30/33 (91) - - - - - 
W.Liu, et al. 2020 [33]  11/19 (58) - 5/19 (26) - - - - - 
Cao, et al. 2020 [34] 2/10 (20) 5/10 (50) 1/10 (10) 1/10 (10) - - - - 
Xu, et al. 2020  [35]  1/5 (20) 3/5 (60) 2/5 (40) - 2/5 (40) - - - 
Hantoushzadeh, et al. 
2020 [36] 
7/7 (100) - 7/7 (100) - 4/9 (44) 4/9 (44) - - 
Hirshberg, et al. 2020 [37] 5/5 (100) - 4/5 (80) - 4/5 (80) - - - 
Qiancheng, et al. 2020  [38] 5/28 (18) - 7 (25) 1 (3.6) 2 (7.1) - - - 
Hu, et al. 2020 [39] 4/7 (57.14) - 2/7 (29) - - - - 1/7 (14) 
Cooke, et al. 2020 [40] 1/2 (50) - 1/2 (50) - 1/2 (50) - - 1/2 (50) 
Doria, et al. 2020  [41] - - - - - - - - 
Lokken, et al.  2020 [42] 23/46 (50) - 32/46 (70) 13/46 (28) 20/46 (44) 14/46(30) 12/46 (28) 3/46 (7) 
Savasi, et al. 2020 [43] 41/77 (53) - 50/77 (65) - 19/77 (25) - - - 
London, et al. 2020 [44] 26/68 (38) - 43/68 (63) - - - - - 
Govind, et al. 2020 [45]  4/9 (44) - 8/9 (89) 6/9 (67) 4/9 (44) 5/9 (56) - - 
Ferrazi, et al. 2020 [46] 20/42 (48) 6/42 (14) 18/42 (43) - 8/42 (19) - - 2/42(5) 
 
Table 5:  Laboratory characteristics 




Na Li et al. 2020 [11]       
Confirmed Case (16) 2/16 (12.5) 5/16 (31.3) 16/276 (6.0) 
Suspected Case (18) 5/18(27.8) 11/18 (61.1) 
Control 2020 (121) 15/121 (12.4) 68/121 (56.2) 
Control 2019 (121) 14/121 (11.6) 57/121 (47.1) 
H.Chen, et al. 2020 [12] 5/9(56) 6/8(75) 9/9(100) 
S.Chen. et al. 2020 [13] 4/5(80) 4/4(100) 5/5(100) 
Zhu et al. 2020 [14] - - 9/9(100) 
Yu, et al. 2020  [15] 5/7(71) 7/7(100) 7/7(100) 
R.Chen, et al. 2020 [16] 25/41 (61) 27/41 (66) 16/41 (39) 
H.Liu, et al. 2020 [17] 25/41 (61) 27/41 (66) 16/41 (39) 
Yang, et al. 2020  [18]       
Confirmed (13) - - 13/13(100) 
Control (42) - - - 
D.Liu, et al. 2020  [19] 12/15(80) 10/15(67) 15/15(100) 
Yan, et al. 2020 [20] 51/116 (44.0) 51/116 (44.0) 65/116(56.0) 




Breslin, et al. 2020b [22] - - 7/7(100) 
C.Wu, et al. 2020 [23] 5/8(62.5) 8/8 (100) 6/6 (100) 
X.Wu, et al. 2020  [24] - - 19/23 (82.6) 
Pierce-Wiliams, et al. 2020 [25]       
Severe (44) - 43.3±45.9 64/64 (100) 
Critical (20) - 141.9±88.6 
Khan, et al. 2020a [26] - 2/3 (66.6) 3/3 (100) 
Fan, et al. 2020 [27] 2/2(100) - 2/2(100) 
Y.Chen, et al. 2020 [28] 4/4(100) 4/4(100) 4/4(100) 
Campbell, et al. 2020 [29] - - 30/30 (100) 
Baergen, et al.  2020 [30] - - 20/20 (100) 
Khan, et al. 2020b [31] 4/17 (24) - 17/17 (100) 
Zheng, et al. 2020 [32] - - 33/33 (100) 
W.Liu, et al. 2020 [33]  - - 19/19 (100) 
Cao, et al. 2020 [34] 1/10 (10) - 10/10 (100) 
Xu, et al. 2020  [35]  - - 5/5 (100) 
Hantoushzadeh, et al. 2020 [36] - 7/9 (78) 7/9(78) 
Hirshberg, et al. 2020 [37] - 1/5 (20) 5/5 (100) 
Qiancheng,  et al. 2020  [38] 8 (28.6) 17 (68) 28/28 (100) 
Hu, et al.  2020 [39] - - 7/7 (100) 
Cooke, et al. 2020 [40] - - 2/2 (100) 
Doria,  et al. 2020  [41] - - 12/12 (100) 
Lokken, et al.  2020 [42] - - 46/46 (100) 
Savasi, et al. 2020 [43] 19/77 (25) 39/77 (51) 77/77 (100) 
London, et al. 2020 [44] 24/68 (35.3) - 68/68 (100) 
Govind, et al. 2020 [45]  2/9 (22) - 9/9 (100) 
Ferrazi, et al. 2020 [46] 6/42 (14) 17/42 (40) 42/42 (100) 
 
Table 6: CT Scan findings 
Authors Unilateral pneumonia Bilateral pneumonia Typical viral infection 
Na Li et al., 2020 [11]       
Confirmed Case (16) 8/16 (50.0) 7/16 (43.8) - 
Suspected Case (18) 10/18 (55.6) 7/18 (38.9) - 
Control 2020 (121) - - - 
Control 2019 (121) - - - 
H.Chen, et al. 2020 [12] - - 8/9(89) 
S.Chen. et Al., 2020 [13] 2/5(40) 3/5(60) - 
Zhu et al. 2020 [14] - - 9/9(100) 
Yu, et al. 2020  [15] 6/7(86) 1/7(14) - 
R.Chen, et al. 2020 [16] 12/41 (29) 26/41 (63) - 
H.Liu, et al. 2020 [17] 12/41 (29) 26/41 (63) - 
D.Liu, et al. 2020  [19] - - 15/15(100) 
Yan, et al. 2020 [20] - - 104/116 (96.3) 
C.Wu, et al. 2020 [23] - - 6/8(75) 




Khan, et al. 2020a  [26] - 3/3 (100) - 
Fan, et al. 2020 [27] 2/2(100) - - 
Y.Chen, et al. 2020 [28] - 4/4 (100) - 
Cao, et al. 2020 [34] 4/10 (40) 6/10 (60) - 
  
Table 7: Treatment 
Authors Treatment 
Steroid Antibiotic Antiviral High throughput O2 ECMO 
Na Li et al. 2020 [11]           
Confirmed Case (16) - 16/16 (100.0) 4/16 (25.0) - - 
Suspected Case (18) - 18/18 (100.0) - - - 
Control 2020 (121) - - - - - 
Control 2019 (121) - - - - - 
H.Chen, et al. 2020 [12] - 9/9(100) 6/9(67) 9/9(100) - 
Yu, et al. 2020  [15] - 7/7(100) 7/7(100) 7/7(100) - 
D.Liu, et al. 2020  [19] - 15/15(100) 11/15(73) 14/15(93) - 
Yan, et al. 2020 [20] 37/116 (31.9) 109/116 (94.0) 63/116 (54.3) 6/116 (5.2) 1/116 (0.9)  
C.Wu, et al. 2020 [23] - 8/8(100) - - - 
Pierce-Wiliams, et al. 2020 [25]           
Severe (44) 4/44  (9%) 22/44 (50%)  3/44 (7%)  5/44  (11%)  - 
Critical (20) 11/20 (55%)  14 /20 (70%) 13/20  (65%)  11/20  (55%) - 
Khan, et al. 2020a [26] - 3/3 (100) 3/3 (100) - - 
Fan, et al. 2020 [27] 2/2(100) 2/2(100) 2/2(100) - - 
Khan, et al. 2020b [31] - 17/17 (100) 16/17 (94) - - 
Xu, et al. 2020  [35]  4/5 (80) 5/5 (100) 5/5 (100) - - 
Hantoushzadeh, et al. 2020 [36] - 9/9 (100) 9/9 (100) - - 
Hirshberg, et al. 2020 [37] 5/5 (100) - 5/5 (100) - - 
Qiancheng, et al. 2020  [38] - 24/28 (85.7) 20/28 (71.4) - - 
Hu, et al.  2020 [39] - - 1/7 (14) - - 
Savasi, et al. 2020 [43] - 27/77 (35) 25/77 (32) 20/77 (26) - 
 
Table 8:  Maternal comorbidities and maternal outcome 




Na Li et al. 2020 [11]         
Confirmed Case (16) 2/16 (12.5) 11/16 (68.8) - - 
Suspected Case (18) 1/18 (5.6) 13/18 (72.2) 
  
Control 2020 (121) 5/121 (4.1) 38/121 (31.4) 
  
Control 2019 (121) - 32/121 (33.3) 
  
H.Chen, et al. 2020 [12] - 7/9(77) - - 
S.Chen. et al. 2020 [13] - 3/5(60) - - 
Zhu et al. 2020 [14] - 4/9(44) - - 
Yu, et al. 2020  [15] 2/7( 29) 3/7(43) - - 
R.Chen, et al. 2020 [16] - 8/17 (47) - - 




Yan, et al. 2020 [20] - 18/116(15.5) 8/116(6.9) - 
Breslin, et al. 2020a [21] - - 2/29 (4.7) - 
Pierce-Williams, et al. 2020 [25]         
Severe (44) 20/44 (45) 9/44 (20) - - 
Critical (20) 7/20 (35) 3/20 (15) - - 
Khan, et al. 2020b [31] - 5/17 (29.4) - - 
Zheng, et al. 2020 [32] - 3/33 (9) - - 
Cao, et al. 2020 [34] - 3/10 (30) - - 
Hantoushzadeh, et al. 2020 [36] 3/9 (33) - 7/9 (77) 7/9 (77) 
Hirshberg, et al. 2020 [37] 5/5 (100) - - - 
Qiancheng, et al. 2020  [38] 6/28 (21.4) 4/28 (14.3) - - 
Cooke, et al. 2020 [40] 2/2 (100) - 2/2 (100) - 
Lokken, et al. 2020 [42] 17/46 (37) - 8/46 (17) - 
Savasi, et al. 2020 [43] - - 14/77 (18) - 
London, et al. 2020 [44] - 4/68 (6) - - 
Ferrazi, et al. 2020 [46] - 6/42 (14) 4/42 (10) - 
 
 

















at 5 minutes 
after birth 
Na Li et al. 2020 [11]             
Confirmed Case (16) - 2/16 (12.5) 3066 .7 ± 560 .2 3/16 (17.6) 9.6 ± 0.5 10.0 ± 0.0 
Suspected Case (18) 
 
1/18 (6.0) 3198 .7 ± 522.6 2/18 (11.0) 9.6 ± 0.5 10.0 ± 0.0 
Control 2020 (121) 
 
6 /121(5.0) 3317.1 ± 455.3 3/121 (2.5) 9.8 ± 0.4 10.0 ± 0.0 
Control 2019 (121) 
 
6/121 (5.0) 3307.9 ± 419.3 3/121 (2.5) 9.9 ± 0.3 10.0 ± 0.0 
H.Chen, et al. 2020 [12] - - 3011 grams 2/9(22) 9 10 
S.Chen. et al. 2020 [13] - - 3691 grams - 10 10 
Zhu et al. 2020 [14] - 6/9(67) 2423 grams 6/9(67) 9 9.4 
Yu, et al. 2020  [15] 
 
- 3264 grams - 9 10 
R.Chen, et al. 2020 [16] - - 3030 grams - 9 10 
Yang, et al. 2020  [18]             
Confirmed (13) - - 3063.2 ± 536.4 - - - 
Control (42) - - 3317.1 ± 522.5 - - - 
D.Liu, et al. 2020  [19] - - - - 8 9 
Yan, et al. 2020 [20] - 9 /99(10.6) 3108 ± 526 - 9 10 
Pierce-Williams, et al. 2020 [25]             
Severe (44) - - 2945.8±509.2  - - 8.8±0.8 
Critical (20) - - 1924.6±846.6  - - 7.2±2.0  
Khan, et al. 2020a [26] - - 3373 - 8.6 9.6 
Fan, et al. 2020 [27] - - 3145 - 9 10 
Y.Chen, et al. 2020 [28] - - 3400 - 8 8 
Campbell, et al. 2020 [29] - - 3370 - - - 




Khan, et al. 2020b [31] - - 3104 - 9 9 
Zheng, et al. 2020 [32] - - - - - - 
W.Liu, et al. 2020 [33]  - - 3293 - 8 9 
Cao, et al. 2020 [34] - - 3003 2/10  (20) 9 10 
Xu, et al. 2020  [35]  - - 2992 1/5 (20) 8 9 
Hantoushzadeh, et al. 2020 36] 3/11(27) 3/11 (27) 2464 5/11 (45) 8 9 
Hirshberg, et al. 2020 [37] - - 1818 3/3 (100) 6 7 
Qiancheng, et al. 2020  [38] - 1/23 (4) - 1/23 (4) 10 10 
Hu, et al.  2020 [39] 
 
- 3331 - 8 9 
Cooke, et al. 2020 [40] - - 1450 2/2 (100) 4 6 
Doria, et al. 2020  [41] - - 2960 3/10 (30) 9 10 
Savasi, et al. 2020 [43] 
 
- 3160 - - 10 
London, et al. 2020 [44] - 1/55 (2) - - - - 
Govind, et al. 2020 [45]  
 
- 3155 1/9 (11) 7 9 
Ferrazi, et al. 2020 [46] 
 
- 3018 - - 9 
 
Discussion  
Clinical Manifestations and Complications during 
Pregnancy 
Based on the earlier evidence of Middle East Respiratory 
Syndrome (MERS) and Severe Acute Respiratory Syndrome 
(SARS) the clinical manifestation of these infections during 
pregnancy varies from asymptomatic presentation to severe 
respiratory illness and mortality. A recent retrospective study 
presented the clinical profile of nine pregnant women diagnosed 
with COVID-19 during the third trimester. The authors reported 
that the clinical presentation of COVID-19 positive pregnant 
women was comparable with the non-pregnant female patients, 
and the frequent symptoms were fever (78%), cough (44%), 
myalgia (33%), sore throat and malaise (22% each). 
Lymphopenia was reported in five patients and none of them 
had developed severe pneumonia that requires mechanical 
ventilation and all survived. All women had a caesarean section 
and the Apgar score was 8-9 at 1 minute and 9-10 at 5 minutes. 
Four out of nine deliveries had pre-term labour but after 36 
gestational weeks and seven patients developed pregnancy 
related-complications [12]. 
Another series of nine COVID-19 positive pregnant women 
with ten infants (one had twins) by Zhu et al., reported onset of 
symptomatic presentation prior to delivery (1-6 days) in four, 
on the day of delivery in two, and post-delivery (1-3 days) in 
three cases [14]. Similar to the earlier report, the clinical 
presentation of COVID-19 cases was comparable to non-
pregnant patients. Of the nine pregnancies, six patients had 
intrauterine foetal distress, seven had a caesarean section, six 
were preterm deliveries and four had pregnancy-related 
complications [14]. 
Yu et al. studied seven pregnant COVID-19 patients with a 
mean age of 32 (range 29–34 years) admitted during early 2020 
[15]. The average gestational age was over 39 weeks. Six 
patients had a fever as their chief clinical manifestation, 
shortness of breath, and cough and diarrhoea in one patient 
each. Caesarean sections were performed in all patients within 
three days of clinical presentation. All women had good 
maternal and neonatal outcomes but one neonate was tested 
positive for COVID-19 36 hours after birth [15]. Wu et al. 
reported eight pregnant patients aged 26 to 35 years [24]. Six of 
these women were laboratory-confirmed and two were highly 
suspected SARSCoV-2 infection cases. Six had caesarean 
sections because of premature rupture of membrane, 
preeclampsia, fetal distress, or the history of caesarean section. 
Notably, intensive care or mechanical ventilation was not 
required in any patients. Four out of eight pregnant women 
remained asymptomatic prior to delivery, but later developed 
symptoms post-partum [24]. Breslin et al. reported seven 
confirmed COVID-19 cases in pregnancy in the USA, presented 
with symptoms such as cough, fevers, myalgia, chest pain, and 
headache. Two patients required supportive care with 
intravenous hydration [22]. Another study from the USA 
described 43 patients, 14 (32.6%) were asymptomatic, later on, 
ten patients developed symptoms during the hospital course or 
early after postpartum discharge [21]. Three required antenatal 
admission for viral symptoms of the other 29 (67.4%) 
symptomatic patients. The disease was mild in 86%, severe in 
9.3%, and critical in 4.7%. Wu et al. demonstrated a significant 
difference in the median time for hospitalisation among 
asymptomatic and symptomatic patients (14 vs. 25.5 days, 




23 pregnant patients diagnosed with COVID-19 and admitted 
to the hospital in Wuhan [24].  
Chen and colleagues [13] reported five young pregnant 
COVID-19 patients aged 25 to 31 years, gestational age from 
38 to 41 weeks, who were admitted to the hospital. The women 
developed low‐grade fever within 24 hours post-partum. The 
renal and liver function profile was unremarkable for all 
patients. CT scan images revealed abnormal bilateral ground‐
glass opacity (three cases) or unilateral lobe (two cases). Three 
had normal births and two underwent caesarean sections; all 
labours were smoothly processed with no maternal or newborn 
complications. The Apgar scores were 10 points at 1 and 5 
minutes after delivery [13]. Liu et al. reported clinical 
differences among pregnant and non-pregnant. The laboratory-
confirmed and clinically diagnosed COVID-19 pregnant 
women had higher initial body temperature, leukocytosis and 
elevated neutrophil ratio, and lymphopenia as compared to 
laboratory-confirmed non-pregnant patients [17]. The CT 
imaging revealed lesions with peripheral (98%) and bilateral 
(67%) distributions. For the non-pregnant adults, pure ground-
glass opacity (72%) was the most frequent finding [17].  
A retrospective study by Zhang et al. compared the pregnancy 
outcomes among COVID-19 positive and negative women 
having similar gestational age and delivered by caesarean 
section [49].  The authors suggested no additional risk of intra-
operative blood loss during delivery with a comparable birth 
weight in both groups. In addition, the two groups were 
comparable for meconium-stained amniotic fluid, foetal 
distress, preterm birth, and neonatal asphyxia between COVID-
19 patients and controls. Based on ten neonates in this study, 
there was no evidence of mother-to-fetal vertical transmission 
of COVID-19 infection [49]. Yang et al. tested the throat swab 
samples within 24 h after birth for COVID-19 which revealed 
no evidence of SARS-CoV-2 transmission from infected 
mother to newborn babies [18]. 
A case-control study conducted by Li et al. [48] included 16 
pregnant women positive for COVID-19 and 18 suspected cases 
in the third trimester admitted to the hospital. Notably, two 
patients were presented with respiratory symptoms (fever and 
cough) on admission. Most of the patients had chest CT 
(computed tomography) scan images suggesting typical 
COVID-19 pneumonia. Similar to other studies, these patients 
had lower white blood cells and neutrophils counts, with 
deranged alanine aminotransferase (ALT) and C-reactive 
protein (CRP) levels on admission compared to controls. 
Postpartum blood investigations revealed increased  
eosinophils, white blood cells, neutrophils and CRP. Three 
women with confirmed COVID-19 and three in the control 
group developed pneumonia and had preterm delivery 
secondary to maternal complications. None of the subjects had 
a respiratory failure in the hospital, all newborns were negative 
for infection, and none had severe neonatal complications [48]. 
Zaigham et al. conducted a systematic review to evaluate the 
maternal and perinatal outcomes in pregnancies with COVID-
19 [50]. The authors included all case reports and series from 
December 8, 2019 and April 1, 2020 and identified a total of 
108 pregnancies. During their third trimester of pregnancy, 
most studies observed women mostly presented with fever 
(68%) and coughing (34%). Lymphocytopenia (59%) with 
elevated CRP (70%) was also common. Most (91%) deliveries 
were by caesarean section and three pregnant women required 
ICU admissions. Overall, there was one neonatal and 
intrauterine death with no maternal mortality [50]. The authors 
concluded that most pregnant women were discharged without 
significant complications, but there are some cases with severe 
maternal morbidity and perinatal deaths secondary to COVID-
19 infection. Also, vertical transmission of the COVID-19 
infection from mother to foetus could not be ruled out [50].  
The emerging evidence also indicates that vertical transmission 
of SARS-COV-2 infection is unlikely, but still considering the 
smaller proportion of pregnant cases, the mode of transmission 
of COVID-19 needs further exploration. Two published reports 
have evidence of IgM antibodies for SARS-COV-2 in neonatal 
serum after birth [23,51]. Since, IgM antibodies are not known 
to cross the placenta, the presence of these antibodies indicates 
the neonatal immune response to maternal in-utero infection. 
Although conflicting results were published in previous case 
reports from China, we must remember that case reports are the 
lowest form of evidence in the hierarchy of evidence [52]. 
These reports found that the samples of amniotic fluid, placenta 
and neonatal throat swabs, cord blood, genital fluid, and breast 
milk were negative for COVID-19 infection, indicating no 
vertical transmission evidence  [12, 14, 29, 48].  This also 
suggests that breastfeeding should be encouraged if at all 
possible, with precautions such as washing hands before 
holding the baby and the mother wearing a face mask during 
breastfeeding. 
Previous studies have reported that SARS-CoV-2 has more 
genetic proximity (88% sequence homology) with two SARS-
like coronaviruses derived from bat i.e. bat-SL-CoVZC45 and 
bat-SL-CoVZXC21, as compared to SARS-CoV-1 (79% 
sequence identity) and MERS-CoV (about 50% identity). 
However, modelling studies using bioinformatics tools showed 
that receptor binding domain structure of SARS-CoV-2 and 
SARS-CoV-1 are similar, which suggests a similar course of 
pathogenesis among the two infections [53-55]. Hence, there is 
a lower possibility of vertical transmission of COVID-19 
infection similar to that of SARS-CoV-1. The pooled clinical 
records of 116 pregnant women with COVID-19 from China 




of infection among pregnant women during the third-trimester 
[20].   
Clinical Management 
Pregnant women are considered high risk, so those with 
suspicion of COVID-19 must be isolated, clinically assessed, 
and investigated for the infection [56]. Zeng et al. reported that 
all six COVID-19 pregnant women in their study had caesarean 
deliveries in their third trimester in negative pressure isolation 
rooms [23]. All mothers should wear masks and medical staff 
should use protective suits and double masks. The infants were 
isolated immediately post delivery, and throat swabs and blood 
specimens were found to be found negative by RT-PCR test 
[23]. The COVID-19 Obstetrics Task Force, from Italy stressed 
the need to isolate newborns from COVID-19-positive and 
symptomatic mothers and use pumps to express breast milk 
[47]. 
Pregnant patients who tested positive for infection must be 
immediately shifted to an isolation ward, ideally an isolation 
ward in a tertiary care hospital equipped with appropriate 
medical facilities and multi-disciplinary team to manage 
severely ill pregnant women. Such patients should be triaged 
and clinically evaluated for risk stratification from the 
beginning. Patients with mild symptoms often have stable vital 
signs, while those with severe pulmonary distress have 
respiratory rate ≥30/min, resting oxygen saturation ≤93%, and 
the ratio of arterial blood oxygen partial pressure 
(PaO2)/oxygen concentration (FiO2) to be ≤300 mmHg [7]. 
Importantly, those with critical illness may develop shock with 
organ dysfunction, a respiratory failure requiring mechanical 
ventilation, extra-corporal membrane oxygenation (ECMO) to 
manage refractory hypoxemia [57]. Universal COVID-19 
testing for all pregnant women closer delivery time will help in 
triaging for hospital isolation, bed assignment, personal 
protective equipment (PPE) by healthcare providers and 
improved neonatal care [58]. 
A multispecialty team of obstetricians, midwives, intensivists, 
microbiologists, anaesthetists and neonatologist should be 
available to manage pregnant women with COVID-19 primarily 
to manage severe and critical cases [59]. Importantly, 
physiological adaptations in pregnancy should be given higher 
consideration while treating pregnant females with confirmed 
diagnosis of COVID-19 infection. For appropriate patient care 
and infection prevention among healthcare workers, the clinical 
staff involved in the care of COVID-19 patients should properly 
use PPE such as N95 masks, gowns, gloves, and goggles [60]. 
However, we need to remember that all pregnant women, 
irrespective of COVID-19 infections, deserve the best quality 
of care pre and post-partum, should be treated with respect and 
dignity; and have an attendant of choice available during 
delivery [61].  
Pregnant women with infection should rest, and be closely 
monitored for adequate nutritional support, hydration, 
electrolyte balance, vital signs and oxygen saturation to 
maintain good physiological status [56]. In patients with acute 
respiratory distress, supplemental oxygen through a high-flow 
nasal cannula should be inspired with 60%-100% concentration 
at a flow rate of 40 L/min, depending upon the severity of 
hypoxemia [62]. In critically ill patients, mechanical ventilatory 
support or extra-corporal membrane oxygenation should be 
considered to maintain oxygen saturation. The other 
complications more common in COVID-19 patients may 
include sepsis and septic shock, acute kidney injury, and virus-
induced cardiac injury [63]. Therefore, in severe cases it is 
crucial to closely monitor the derangement of arterial blood 
gases, serum lactate, renal and liver function profile and cardiac 
enzymes as clinical indicators of physiologic deterioration. 
In China, the antiviral treatment has been administered 
routinely to manage COVID-19 patients which some 
recommended even for pregnant patients [56].  Particularly,  
combination therapy of antiproteases namely 
Lopinavir/Ritonavir is preferred and considered a relatively 
safer drug regimen in pregnant COVID-19 patients. It is 
recommended to have oral administration of Lopinavir/ 
Ritonavir (200 mg/50 mg per capsule) two capsules orally twice 
a day along with the inhalation of nebulised α-interferon (5 
million IU in 2 mL of sterile water for injection) twice daily 
[64]. The World Health Organization (WHO) suggested taking 
precautions and judicious risk-benefit assessment prior to 
administering of any therapeutic drug among pregnant females 
except for clinical trials. Interestingly, Remdesivir a nucleotide 
analogue, and chloroquine/hydroxychloroquine, a known 
antimalarial drug, are emerging potential therapeutic agents 
against COVID-19 which inhibit the SARS-COV-2 virus 
replication in in-vitro studies [65]. In-vitro studies 
demonstrated inhibition activity of Chloroquine against SARS-
COV-2 virus and potentially minimised the duration of viral 
shedding. However, we are waiting for the outcomes of various 
clinical trials to assess the therapeutic implication of these drugs 
in human subjects. More recently the ISIDOG guidelines 
reminded us that anti-retrovirals are not indicated in pregnancy 
unless there are no other treatment options available to manage 
severe illness [7]  
The SARS-CoV-2 virus is known to cause extensive pulmonary 
damage that eventually enhances the possibility of secondary 
bacterial pneumonia [66]. Therefore, the administration of 
antibiotics prophylaxis is primarily recommended, if there is a 
diagnosis of secondary bacterial infection. Moreover, antibiotic 
treatment should be initiated immediately if bacterial sepsis is 




Ceftriaxone can be initiated even before the availability of 
culture and sensitivity results. 
To date, there is no available standard treatment for COVID-19, 
so novel or off-labelled drug should be considered 
experimental, and a detailed explanation has to be provided to 
the patients and partner prior to administration. For instance, 
Corticosteroids can be used to prevent neonatal lung 
hypoplasia, necrotic enterocolitis and interventricular 
haemorrhage due to prematurity. Although, (Hydro) 
chloroquine is considered a safe drug for pregnant women, all 
precautions must be considered before administration in 
COVID-19 patients.  
 
Prevention 
Evidence suggested that the incubation period of COVID19 
ranges from 2-14 days, but the infected individual can also 
transmit the virus despite being asymptomatic during this 
period. Therefore, pregnant women should avoid public 
transport, crowds, contact with sick people, unnecessary travel, 
maintain appropriate social and personal hygiene, including 
proper washing of hands as per recommendation [20]. 
Moreover, pregnant women with symptoms of cough, fever, 
myalgia, fatigue, sore throat or shortness of breath should seek 
immediate medical consultation. Women with a clinical 
suspicion of COVID-19 infection and travel history must be 
isolated and investigated [67]. Also, there is a need to provide 
professional psychological support to overcome mental health 
ilness among pregnant women at risk of developing severe 
anxiety and depression [68]. 
As per the current guidelines of the UK’s Royal College of 
Obstetricians and Gynaecologists (RCOG), the Royal College 
of Midwives (RCM), and the Royal College of Paediatrics and 
Child Health (RCPCH), health workers exceeding 28 weeks of 
pregnancy must avoid direct patients contact whether they are 
infected with COVID-19 or not [69, 70]. However, healthcare 
professionals with less than 28 weeks of pregnancy, can directly 
deal with the patients using appropriate PPEs. It is advisable to 
have a more precautionary approach for pregnant women 
completed 28 weeks’ gestation, or those with underlying co-
mobidities such as heart or lung diseases woking in clinical 
services. If possible, such females should work from home, stay 
away from infected individuals, and avoid unnecessary social 
contact, Moreover, under these circumstances the healthcare 
workers have opportunities for flexible working capacity and 
newer approaches such as telephone or video conference 
consultations, or assigned administrative duties [70]. 
With this outbreak, there is a realisation to strengthen our 
healthcare capacity to tackle the emergent novel outbreaks, 
propose stringent regulations to contain the spread of infectious 
diseases and implement public education among families, 
communities and other religious groups to avoid further 
outbreak and preparedness though transparency and solidarity. 
In order to avoid delayed responses to an outbreak by the 
administration, timely reporting of emergent infectious agents 
is of paramount importance [71]. Proper infection control and 
preventive measures should be implemented in the healthcare 
facilities through isolation of confirmed cases and 
recommended PPE to protect medical professionals and other 
healthcare staff from exposure to communicable diseases [72]. 
It is worth noting that this extensive systematic review only 
cover papers published in 2020, and hence studies conducted in 
or before 2020.  This was before the emergence of variants of 
COVID-19, especially the delta and omicron variants. 
 
Conclusion 
The COVID-19 outbreak is exponentially increasing 
worldwide. A better understanding of the disease transmission, 
major risk factors, vulnerable population, and the outcome is 
crucial for prevention and management. At present, limited 
information is available for pregnant women with COVID-19 
to propose best practices for specialised care. However, the 
current literature suggests that pregnant women with COVID-
19 infection may develop severe clinical manifestations. 
Therefore, surveillance systems for COVID-19 positive patients 
are being established to analyse the maternal and foetal 
outcomes during pregnancy. Also, awareness about the 
management of COVID-19 positive pregnancies and prevention 
of neonatal infection is vital portant for healthcare 
professionals. Proper vigilance and monitoring of the disease 
spread and rapid implementation of preventive measures are 
crucial to containing the spread of infection in the community. 
The ready availability of standard respiratory support to manage 
severe COVID-19 infection in pregnancy is crucial and should 
be implemented rigorously by a multidisciplinary team. For 
better understanding it is essential to have systematic data 
reporting for evidence based clinical assessment, management, 
and pregnancy outcomes in infected females that will guide the 
healthcare facilities with limited resources to manage the 




All authors have made substantial contributions to all of the 
following: (1) the conception and design of the study, or 
acquisition of data, or analysis and interpretation of data, (2) 
drafting the article or revising it critically for important 








There is no conflict of interest for any author of this manuscript. 
Source of Support: 
This research did not receive any specific grant from funding 
agencies in the public, commercial, or not-for-profit sector. 
Authors’ affiliations: 
1,7,11Geriatrics and long term care Department, Rumailah 
Hospital, Hamad Medical Corporation, Doha, Qatar 
2Sir Seewoosagur Ramgoolam Medical College, Mauritius 
3,6 Trauma Surgery, Hamad General Hospital, Doha, Qatar 
1,4,9Bournemouth University, Bournemouth, England, United 
Kingdom 
5Clinical Research Center, Fundación Valle del Lili. Cali, 
Colombia 
8School of Allied Health, Faculty of Health, Education, 
Medicine, and Social Care, Anglia Ruskin University, 
Chelmsford, United Kingdom 
9University of Huddersfield, United Kingdom  
10University Hospital and School of Medicine, Federal 
University of Minas Gerais, Belo Horizonte, Minas Gerais, 
Brazil 
11Medical Director, Rumailah Hospital (RH) & Qatar 
Rehabilitation Institute (QRI), Doha, Qatar. 
References 
 
1. COVID-19 Coronavirus Pandemic. [Online] 2020 [Cited 
2020 Apr 27]. Available from: URL 
https://www.worldometers.info/coronavirus/?utm_campaign=
homeAdvegas1?%22%20%5Cl%20%22countriess/ 
2. Rasmussen SA, Hayes EB. Public health approach to 




3. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 
2009 influenza A(H1N1) virus illness among pregnant women 
in the United States. JAMA. 2010;303:1517-25. 
https://doi.org/10.1001/jama.2010.479 
PMid:20407061 PMCid:PMC5823273  
4. Moore CA, Staples JE, Dobyns WB, ,et al. Characterizing the 
pattern of anomalies in congenital Zika syndrome for pediatric 
clinicians. JAMA Pediatr. 2017;171:288-95. 
https://doi.org/10.1001/jamapediatrics.2016.3982 
PMid:27812690 PMCid:PMC5561417 
5. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika 
virus and birth defects--Reviewing the evidence for causality. 
N Engl J Med. 2016;374:1981-7. 
https://doi.org/10.1056/NEJMsr1604338 
PMid:27074377 
6. Dashraath P, Wong JLJ, Lim MXK, et al. Coronavirus 
Disease 2019 (COVID-19) Pandemic and Pregnancy. Am J 
Obstet Gynecol. 2020:S0002-9378:30343-4.  
https://doi.org/10.1016/j.ajog.2020.03.021 
PMid:32217113 PMCid:PMC7270569 
7. Donders F, Lonnee-Hoffmann R, Tsiakalos A,  et al. ISIDOG 
recommendations concerning COVID-19 and pregnancy. 
ISIDOG Recommendations Concerning COVID-19 and 
Pregnancy. Diagnostics. 2020;10:243.  
https://doi.org/10.3390/diagnostics10040243 
PMid:32338645 PMCid:PMC7235990 
8. Haddad LB, Jamieson DJ, Rasmussen SA. Pregnant women 
and the Ebola crisis. N Engl J Med. 2018;379:2492-3. 
https://doi.org/10.1056/NEJMp1814020 
PMid:30485156 
 9. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-
Ocampo E, et al. Latin American Network of Coronavirus 
Disease 2019-COVID-19 Research (LANCOVID-19). Clinical, 
laboratory and imaging features of COVID-19: A systematic 
review and meta-analysis. Travel Med Infect Dis. 2020:101623.  
https://doi.org/10.1016/j.tmaid.2020.101623 
PMid:32179124 PMCid:PMC7102608 
10. Chen N, Zhou M, Dong X, et al. Epidemiological and 
clinical characteristics of 99 cases of 2019 novel coronavirus 
pneumonia in Wuhan, China: a descriptive study. Lancet. 
2020;395:507-13. 
https://doi.org/10.1016/S0140-6736(20)30211-7 
11. Li N, Han L, Peng M, et al. Maternal and Neonatal 
Outcomes of Pregnant Women With Coronavirus Disease 2019 
(COVID-19) Pneumonia: A Case-Control Study. Clin Infect 
Dis. 2020 Nov 19;71(16):2035-2041. 
https://doi.org/10.1093/cid/ciaa352 
PMid:32249918 PMCid:PMC7184430 
12. Chen H, Guo J, Wang C, et al. Clinical characteristics and 
intrauterine vertical transmission potential of COVID-19 
infection in nine pregnant women: a retrospective review of 
medical records. Lancet. 2020 Mar 7;395(10226):809-815. 
Erratum in: Lancet. 2020 Mar 28;395(10229):1038.  
https://doi.org/10.1016/S0140-6736(20)30360-3 
PMiD: 32151335; PMCiD: PMC7159281. 
13. Chen S, Liao E, Cao D, Gao Y, Sun G, Shao Y. Clinical 
analysis of pregnant women with 2019 novel coronavirus 
pneumonia. J Med Virol. 2020 Sep;92(9):1556-1561.  
https://doi.org/10.1002/jmv.25789 
PMid:32222119 PMCid:PMC7228212  
14. Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 
neonates born to mothers with 2019-nCoV pneumonia. Transl 
Pediatr. 2020 Feb;9(1):51-60.. 
https://doi.org/10.21037/tp.2020.02.06 
PMid:32154135 PMCid:PMC7036645 
15. Yu N, Li W, Kang Q, et al. Clinical features and obstetric 
and neonatal outcomes of pregnant patients with COVID-19 in 
Wuhan, China: a retrospective, single-centre, descriptive study. 
Lancet Infect Dis. 2020 May;20(5):559-564 
https://doi.org/10.1016/S1473-3099(20)30176-6 
PMiD: 32220284; PMCiD: PMC7158904.  
16. Chen R, Zhang Y, Huang L, Cheng BH, Xia ZY, Meng QT. 
Safety and efficacy of different anesthetic regimens for 
parturients with COVID-19 undergoing Cesarean delivery: a 







17. Liu H, Liu F, Li J, Zhang T, Wang D, Lan W. Clinical and 
CT imaging features of the COVID-19 pneumonia: Focus on 
pregnant women and children. J Infect. 2020 May;80(5):e7-e13.  
https://doi.org/10.1016/j.jinf.2020.03.007 
PMid:32171865 PMCid:PMC7156118 
18. Yang H, Sun G, Tang F, et al. Clinical features and 
outcomes of pregnant women suspected of coronavirus disease 
2019. J Infect. 2020 Jul;81(1):e40-e44.  
https://doi.org/10.1016/j.jinf.2020.04.003 
PMid:32294503 PMCid:PMC7152867 
19. Liu D, Li L, Wu X, et al. Pregnancy and Perinatal Outcomes 
of Women With Coronavirus Disease (COVID-19) Pneumonia: 




20. Yan J, Guo J, Fan C et al. Coronavirus disease 2019 in 
pregnant women: a report based on 116 cases. Am J Obstet 
Gynecol. 2020 Jul;223(1):111.e1-111.e14.  
https://doi.org/10.1016/j.ajog.2020.04.014 
PMid:32335053 PMCid:PMC7177142 
21. Breslin N, Baptiste C, Gyamfi-Bannerman C, et al. 
Coronavirus disease 2019 among asymptomatic and 
symptomatic pregnant women: two weeks of confirmed 
presentations to an affiliated pair of New York City hospitals. 
Am J Obstet Gynecol MFM 2020a;2:100118. 
https://doi.org/10.1016/j.ajogmf.2020.100118 
PMid:32292903 PMCid:PMC7144599 
22. Breslin N, Baptiste C, Miller R, et al. Coronavirus disease 
2019 in pregnancy: early lessons. Am J Obstet Gynecol MFM. 
2020b May;2(2):100111.  
https://doi.org/10.1016/j.ajogmf.2020.100111 
PMid:32518902 PMCid:PMC7271091 
23. Wu C, Yang W, Wu X, et al. Clinical Manifestation and 
Laboratory Characteristics of SARS-CoV-2 Infection in 
Pregnant Women. Virol Sin. 2020 Jun;35(3):305-310.  
https://doi.org/10.1007/s12250-020-00227-0 
PMid:32314274 PMCid:PMC7167538 
24. Wu X, Sun R, Chen J, Xie Y, Zhang S, Wang X. 
Radiological findings and clinical characteristics of pregnant 
women with COVID-19 pneumonia. Int J Gynaecol Obstet. 
2020 Jul;150(1):58-63.  
https://doi.org/10.1002/ijgo.13165 
PMid:32270479 
25. Pierce-Williams RAM, Burd J, Felder L, et al. Clinical 
course of severe and critical coronavirus disease 2019 in 
hospitalized pregnancies: a United States cohort study. Am J 
Obstet Gynecol MFM. 2020 Aug;2(3):100134.  
https://doi.org/10.1016/j.ajogmf.2020.100134 
PMid:32391519 PMCid:PMC7205698 
26. Khan S, Peng L, Siddique R, Nabi G, Nawsherwan, Xue M, 
Liu J, Han G. Impact of COVID-19 infection on pregnancy 
outcomes and the risk of maternal-to-neonatal intrapartum 
transmission of COVID-19 during natural birth. Infect Control 
Hosp Epidemiol. 2020a Jun;41(6):748-750. 
https://doi.org/10.1017/ice.2020.84 
PMid:32279693 PMCid:PMC7156579 
27. Fan C, Lei D, Fang C, et al. Perinatal Transmission of 2019 
Coronavirus Disease-Associated Severe Acute Respiratory 
Syndrome Coronavirus 2: Should We Worry? Clin Infect Dis. 
2021 Mar 1;72(5):862-864. 
https://doi.org/10.1093/cid/ciaa226 
PMid:32182347 PMCid:PMC7184438 
28. Chen Y, Peng H, Wang L, et al. Infants Born to Mothers 




29. Campbell KH, Tornatore JM, Lawrence KE, et al. 
Prevalence of SARS-CoV-2 Among Patients Admitted for 




30. Baergen RN, Heller DS. Placental Pathology in Covid-19 
Positive Mothers: Preliminary Findings. Pediatr Dev Pathol. 
2020 May-Jun;23(3):177-180.  
https://doi.org/10.1177/1093526620925569 
PMid:32397896 PMCid:PMC7252218 
31. Khan S, Jun L, Nawsherwan, et al. Association of COVID-
19 with pregnancy outcomes in health-care workers and general 
women. Clin Microbiol Infect. 2020b Jun;26(6):788-790.  
https://doi.org/10.1016/j.cmi.2020.03.034 
PMid:32278081 PMCid:PMC7141623 
32. Zeng L, Xia S, Yuan W,et al. Neonatal Early-Onset 
Infection With SARS-CoV-2 in 33 Neonates Born to Mothers 




33. Liu W, Wang J, Li W, Zhou Z, Liu S, Rong Z. Clinical 
characteristics of 19 neonates born to mothers with COVID-19. 
Front Med. 2020 Apr;14(2):193-198.  
https://doi.org/10.1007/s11684-020-0772-y 
PMid:32285380 PMCid:PMC7152620 
34. Cao D, Yin H, Chen J, et al. Clinical analysis of ten pregnant 
women with COVID-19 in Wuhan, China: A retrospective 
study. Int J Infect Dis. 2020 Jun;95:294-300.  
https://doi.org/10.1016/j.ijid.2020.04.047 
PMid:32335338 PMCid:PMC7179499 
35. Xu L, Yang Q, Shi H, et al. Clinical presentations and 
outcomes of SARS-CoV-2 infected pneumonia in pregnant 
women and health status of their neonates. Sci Bull (Beijing). 
2020 Sep 30;65(18):1537-1542.  
https://doi.org/10.1016/j.scib.2020.04.040 
PMid:32346493 PMCid:PMC7186128 
36. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, et al. 








of critically ill pregnant patients with coronavirus disease 2019: 
a case series. Am J Obstet Gynecol. 2020 Aug;223(2):286-290.  
https://doi.org/10.1016/j.ajog.2020.04.029 
PMid:32371056 PMCid:PMC7252050 
38. Qiancheng X, Jian S, Lingling P, et al. Coronavirus disease 
2019 in pregnancy. Int J Infect Dis. 2020 Jun;95:376-383. = 
https://doi.org/10.1016/j.ijid.2020.04.065 
PMid:32353549 PMCid:PMC7185021 
39. Hu X, Gao J, Luo X, et al. Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS-CoV-2) Vertical 
Transmission in Neonates Born to Mothers With Coronavirus 




40. Cooke WR, Billett A, Gleeson S, et al. SARS-CoV-2 
infection in very preterm pregnancy: Experiences from two 




41. Dória M, Peixinho C, Laranjo M, Mesquita Varejão A, Silva 
PT. Covid-19 during pregnancy: A case series from an 
universally tested population from the north of Portugal. Eur J 
Obstet Gynecol Reprod Biol. 2020 Jul;250:261-262 
https://doi.org/10.1016/j.ejogrb.2020.05.029 
PMid:32425298 PMCid:PMC7227580  
42. Lokken EM, Walker CL, Delaney S, et al. Clinical 
characteristics of 46 pregnant women with a severe acute 
respiratory syndrome coronavirus 2 infection in Washington 
State. Am J Obstet Gynecol. 2020 Dec;223(6):911.e1-911.e14.  
https://doi.org/10.1016/j.ajog.2020.05.031 
PMid:32439389 PMCid:PMC7234933 
43. Savasi VM, Parisi F, Patanè L, et al. Clinical Findings and 
Disease Severity in Hospitalized Pregnant Women With 




44. London V, McLaren R Jr, Atallah F, et al. The Relationship 
between Status at Presentation and Outcomes among Pregnant 




45. Govind A, Essien S, Karthikeyan A, Fakokunde A, Janga 
D, Yoong W, Nakhosteen A. Re: Novel Coronavirus COVID-
19 in late pregnancy: Outcomes of first nine cases in an inner 




46. Ferrazzi EM, Frigerio L, Cetin I, et al. COVID-19 Obstetrics 
Task Force, Lombardy, Italy: Executive management summary 




47. Li N, Han L, Peng M,  et al. Maternal and neonatal outcomes 
of pregnant women with COVID-19 pneumonia: a case-control 
study. Clin Infect Dis. 2020;pii: ciaa352.  
https://doi.org/10.1093/cid/ciaa352 
PMid:32249918 PMCid:PMC7184430 
48. Zhang L, Jiang Y, Wei M,  et al. [Analysis of the pregnancy 
outcomes in pregnant women with COVID-19 in Hubei 




49. Zaigham M, Andersson O. Maternal and Perinatal 
Outcomes with COVID-19: a systematic review of 108 
pregnancies. Acta Obstet Gynecol Scand. 2020 Apr 7.  
https://doi.org/10.1111/aogs.13867 
PMid:32259279 PMCid:PMC7262097 
50. Dong L, Tian J, He S, , et al. Possible Vertical Transmission 




51. Murad MH, Asi N, Alsawas M, Alahdab F. New evidence 
pyramid. Evid Based Med.  
2016;21:125-7.  
https://doi.org/10.1136/ebmed-2016-110401 
PMid:27339128 PMCid:PMC4975798  
52. Lu R, Zhao X, Li J,et al. Genomic characterisation and 
epidemiology of 2019 novel coronavirus: implications for virus 
origins and receptor binding. Lancet. 2020;395(10224):565-74.  
https://doi.org/10.1016/S0140-6736(20)30251-8 
PMiD: 32007145 PMCiD: PMC7159086 
53. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, 
van Goor H. Tissue distribution of ACE2 protein, the functional 
receptor for SARS coronavirus. A first step in understanding 
SARS pathogenesis. J Pathol 2004;203: 631-7. 
https://doi.org/10.1002/path.1570 
PMid:15141377 PMCid:PMC7167720 
54. To KF, Lo AW. Exploring the pathogenesis of severe acute 
respiratory syndrome (SARS): the tissue distribution of the 
coronavirus (SARS-CoV) and its putative receptor, 




55. Liang H, Acharya G. Novel corona virus disease (COVID‐
19) in pregnancy: What clinical recommendations to follow? 
Acta Obstet Gynecol Scand, 99: 439-42.  
https://doi.org/10.1111/aogs.13836 
PMid:32141062 
56. Zeng H, Xu C, Fan J, et al. Antibodies in Infants Born to 
Mothers With COVID-19 Pneumonia. JAMA. 2020 May 
12;323(18):1848-1849.  
https://doi.org/10.1001/jama.2020.4861 
PMiD: 32215589; PMCiD: PMC7099444.  






58. Sutton D, Fuchs K, D'Alton M, Goffman D. Universal 
Screening for SARS-CoV-2 in Women Admitted for Delivery . 
N Engl J Med. 2020.  
https://doi.org/10.1056/NEJMc2009316 
PMid:32283004 PMCid:PMC7175422 
59. Queensland Clinical Guidelines Perinatal care of suspected 
or confirmed COVID-19 pregnant women. Guideline No. 
MN20.63-V2-R25. Queensland Health. 2020. Available from: 
http://www.health.qld.gov.au/qcg. 
60. Infection prevention and control during health care when 
novel coronavirus (CAUVID-19) infection is suspected Interim 
guidance. Available at: https://www.who.int/publications-
detail/infection-prevention-andcontrol-during-health-care-
when-novel-coronavirus-(ncov)-infection-issuspected. 
61. WHO 2020. Q&A on COVID-19, pregnancy, childbirth and 
breastfeeding 18 March 2020. Available at: 
https://www.who.int/news-room/q-a-detail/q-a-on-covid-19-
pregnancy-childbirth-and-breastfeeding 
Accessed: 14 April 2020 
62. Clinical management of severe acute respiratory infection 
when Novel coronavirus (2019‐nCoV) infection is suspected: 
Interim Guidance. WHO/nCoV/Clinical/2020.3 January 28 
2020. 
63. Matos R, Chung KK. DoD COVID-19 practice management 




Accessed: 16 April 2020 
64. Song Y, Zhang M, Yin L, et al. COVID-19 treatment: close 
to a cure? A rapid review of pharmacotherapies for the novel 
coronavirus (SARS-CoV-2). Int J Antimicrob Agents. 2020 
Aug;56(2):106080. 
https://doi.org/10.1016/j.ijantimicag.2020.106080. 
PMiD: 32634603 PMCiD: PMC7334905 
65. Wang M, Cao R, Zhang L, et al. Remdesivir and 
chloroquine effectively inhibit the recently emerged novel 
coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71.  
https://doi.org/10.1038/s41422-020-0282-0 
PMid:32020029 PMCid:PMC7054408 
66. Coronavirus disease 2019 (COVID-19) pandemic: 
increased transmission in the EU/EEA and the UK - seventh 
update, 25 March 2020. Stockholm: ECDC; 2020. 
67. Asadi L, Tabatabaei R S, Safinejad H, Mohammadi M. New 
Corona Virus (COVID-19) Management in Pregnancy and 
Childbirth. Arch Clin Infect Dis. Online ahead of Print ; 
15(COVID-19):e102938.  
https://doi.org/10.5812/archcid.102938 
68. Rashidi Fakari F, Simbar M. Coronavirus Pandemic and 
Worries during Pregnancy; a Letter to Editor. Arch Acad Emerg 
Med. 2020 Mar 16;8(1):e21. 
PMiD: 32185371; PMCiD: PMC7075675. 
69. Rimmer Abi. Covid-19: doctors in final trimester of 




70. Royal College of Obstetricians and Gynaecologists. 
Coronavirus (COVID-19) infection in pregnancy: information 
for healthcare professionals (version 2). 13 March 2020. 
www.rcog.org.uk/globalassets/documents/guidelines/2020-03-
21-covid19-pregnancy-guidance-2118.pdf. 
71. Bonačić Marinović A, Swaan C, van Steenbergen J, 
Kretzschmar M. Quantifying reporting timeliness to improve 




72. Guidance on Preparing Workplaces for COVID-19. 
Occupational Safety and Health Administration 2020. 
https://www.osha.gov/Publications/OSHA3990.pdf 
 
